QPS Holdings, LLC and Hepregen Corporation have announced the execution of an agreement between the companies that provides QPS a license to offer drug metabolism and pharmacokinetic (“DMPK”) services to its clients using Hepregen’s products. The agreement provides for offerings in both North America and Europe. The agreement also creates a marketing and sales partnership between the companies, providing for co-promotion of the HepatoPacTM-associated DMPK services. This arrangement is the first such partnership in the field for both companies.
QPS expects to begin offering metabolite identification, profiling, and clearance studies to North American customers before the end of June, and to European customers in the third calendar quarter of this year using HepatoPacTM products. The North American services will be offered from its well established DMPK department in Newark, Delaware, and its newly established DMPK Hepatic Biosciences division based at the Hamner Institutes in Research Triangle Park, North Carolina, using rat, dog, monkey and human HepatoPacTM products.
“Our ability to offer services utilizing Hepregen’s next-generation product portfolio is another demonstration of the QPS commitment to enhancing its leadership position in the ADME field, providing cutting-edge, liver-based in vitro services to the pharmaceutical and agrochemical industry,” stated Dr. Zamas Lam, QPS Senior Vice President of Preclinical Development.
“QPS brings an extraordinary capability and expertise in bioanalytical technology and hepatic cell biology to our partnership and a strong commitment to a progressive vision in the growing field of hepatic sciences,” stated Dr. Vincent Zurawski, Hepregen’s Chief Executive. “Moreover, QPS is an exceptionally well-managed company, as demonstrated by its outstanding record of growth in the last five years. We are extremely pleased to be engaged with such a strong partner in this paradigm-shifting endeavor,” added Dr. Zurawski.